Insulet Has Received CE Mark Approval Under The European Medical Device Regulation For The Added Compatibility Of The Abbott FreeStyle Libre 2 Plus Sensor With Insulet's Omnipod 5 Automated Insulin Delivery System For Individuals Aged Two Years And Older
Portfolio Pulse from Benzinga Newsdesk
Insulet has received CE Mark approval for the compatibility of the Abbott FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older under the European Medical Device Regulation.
February 07, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott's FreeStyle Libre 2 Plus sensor's compatibility with Insulet's Omnipod 5 could strengthen its position in the diabetes management market by expanding its usage and integration with leading insulin delivery systems.
The compatibility of Abbott's FreeStyle Libre 2 Plus sensor with Insulet's Omnipod 5 Automated Insulin Delivery System underlines a strategic partnership that could enhance Abbott's standing in the diabetes management market. This integration allows for broader usage of the FreeStyle Libre 2 Plus sensor, potentially increasing its adoption and reinforcing Abbott's position in the market.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Insulet's CE Mark approval for Omnipod 5 and FreeStyle Libre 2 Plus sensor compatibility could enhance its product offering in Europe, potentially increasing its market share and customer base.
The CE Mark approval is a significant regulatory milestone that allows Insulet to market its enhanced Omnipod 5 system in Europe. This approval could lead to increased adoption of the Omnipod 5 system, as it now supports the widely used Abbott FreeStyle Libre 2 Plus sensor, potentially increasing Insulet's market share and customer base in the region.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90